KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Cash from Discontinued Operations (2020 - 2021)

Merck (MRK) reported Cash from Discontinued Operations of 702000000.0 for Q4 2021, down 236.31% year-over-year from 515000000.0 in Q4 2020, and down 210.03% on a QoQ basis from 638000000.0 in Q3 2021.

Merck (MRK) has 2 years of Cash from Discontinued Operations data on file, last reported at 702000000.0 in Q4 2021.

  • Quarterly Cash from Discontinued Operations fell 236.31% year-over-year to 702000000.0 in Q4 2021, while the trailing twelve-month figure through Sep 2022 was 702000000.0 (down 144.83% YoY) and the FY2021 annual result came in at 349000000.0, down 85.37% from the prior year.
  • Cash from Discontinued Operations fell to 702000000.0 in Q4 2021 per MRK's latest filing, from 638000000.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 638000000.0 in Q3 2021 and bottomed at 702000000.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 -702.00 Mn
Dec 31, 2021 -702.00 Mn
Sep 30, 2021 638.00 Mn
Sep 30, 2021 638.00 Mn
Jun 30, 2021 -86.00 Mn
Jun 30, 2021 -86.00 Mn
Mar 31, 2021 499.00 Mn
Mar 31, 2021 499.00 Mn
Dec 31, 2020 515.00 Mn
Dec 31, 2020 515.00 Mn
Sep 30, 2020 522.00 Mn
Sep 30, 2020 522.00 Mn